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Exposure to aflatoxins (AFs) in the diet may favour the development of hepatocellular carcinoma (HCC) 
and the acute exacerbation of hepatitis in chronic hepatitis B virus (HBV) carriers. Measurement of 
biomarkers such as aflatoxin M1 (AFM1), a metabolite of aflatoxin B1 (AFB1), in urine allows for the 
assessment of populations exposed to aflatoxins. The aim of this study was to investigate the occurrence 
of aflatoxin M1 in the urine of HBV carrier and non-carrier patients. One group included 43 randomly 
selected HBV carriers treated at two hospitals in the city of Maringa, Brazil, from March to June 2008. 
Control group consisted of 29 healthy adult volunteers with anti-HBs positive and HBsAg negative test 
results. Detection of AFM1 was performed by fluorescence using high performance liquid chromatography 
(HPLC) and post-column derivation with the Kobra Cell®. Of the 72 samples analysed, 05/29 (17.2%) 
AFM1 positive samples were from HBV non-carriers, and 16/43 (37.2%) of samples were from chronic 
HBV carriers. This study showed AFM1 in the urine of the two surveyed population. However, there is 
evidence that the chronic HBV carriers have a higher risk of developing HCC due to additive interaction 
between AFs and HBV.
Uniterms: Aflatoxins. Biomarkers. Hepatitis B. Hepatocellular carcinoma. Urina/análise toxicológica. 
Epidemiology.
A exposição às aflatoxinas (AFs) na dieta é um fator de risco para o desenvolvimento do carcinoma 
hepatocelular (CHC) e a exacerbação da hepatite aguda em indivíduos portadores do vírus da hepatite B 
(VHB). O uso de biomarcadores, como a aflatoxina M1 (AFM1) na urina, produto de biotransformação 
da aflatoxina B1 (AFB1), permite avaliar se a população está exposta às AFs. O objetivo do presente 
estudo foi investigar ocorrência de AFM1 na urina de portadores e não portadores crônicos do VHB. 
Foi selecionado um grupo, de forma aleatória, representado por 43 portadores do VHB atendidos em 
dois hospitais da cidade de Maringá, Brasil, no período de Março a Junho/2008. O grupo controle foi 
composto por 29 voluntários adultos saudáveis anti-HBs positivo e HBsAg negativo. A determinação 
de AFM1 foi realizada por meio de detecção por fluorescência em sistema de cromatografia a líquido 
de alta eficiência com derivação pós-coluna utilizando Kobra Cell®. Das 72 amostras analisadas, 05/29 
(17,2%) foram positivas para AFM1 em indivíduos não portadores do VHB, e 16/43 (37,2%) de pacientes 
portadores do VHB. Este estudo demonstrou a ocorrência de AFM1 na urina dos dois grupos estudados. 
Entretanto, há evidências de que os portadores do VHB possuam alto risco no desenvolvimento do CHC 
devido ao efeito aditivo pela interação entre aflatoxinas e VHB.
Unitermos: Aflatoxinas. Biomarcadores. Hepatite B. Carcinoma hepatocelular. Análise toxicológica. 
Epidemiologia.
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INTRODUCTION
Aflatoxins (AFs) are a group of mycotoxins of 
major importance in foods such as peanuts and corn. The 
most important toxigenic fungi producing aflatoxins are 
Aspergillus flavus, A. parasiticus and A. nomius. The 
four aflatoxins naturally found in foods are B1 (AFB1), B2 
(AFB2), G1 (AFG1) and G2 (AFG2). Aflatoxin M1 (AFM1) 
is a hydroxylated product of AFB1 that can be secreted 
through body fluids (Creppy, 2002). The action of these 
toxins can cause alterations in the growth of children and 
adolescents, neurological and immunological disorders 
and hepatocellular carcinoma (Eaton, Gropman, 1994; 
Zhang et al., 2012).
Human exposure to aflatoxins is a global concern, as 
studies have reported an association between exposure to 
aflatoxins in the diet and infection with hepatitis B virus 
(HBV) that may favour the development of hepatocellular 
carcinoma (HCC) and the acute exacerbation of hepatitis 
in chronic HBV carriers (Peers et al., 1987; Kensler et al., 
2003). In areas with high incidence of HBV and aflatoxin 
contaminated foods, such as sub-Saharan Africa, Southeast 
Asia and China, the risk of HCC is high. Of the 550,000-
600,000 new HCC cases worldwide each year, about 
25,200-155,000 may be attributable to aflatoxin exposure 
(Liu, Wu, 2010).
One method for estimating exposure to aflatoxins 
in the diet is to determine the concentration and rate of 
consumption in contaminated foods, but several fac-
tors complicate this assessment. Thus, the detection of 
mycotoxins or their metabolites in body fluids such as 
milk, blood and urine allows a quantitative assessment of 
exposure (Groopman, Wogan, 1994; Bando et al., 2007). 
AFB1, an indicator of recent exposure and AFB-albumin 
adducts, which is indicator of long-term exposure, can be 
detected in blood samples (Wang et al., 2001; Bando et al., 
2007). Aflatoxin M1 (AFM1), aflatoxin P1 (AFP1), aflatoxin 
Q1 (AFQ1) and AFB1-N7-guanine adducts are biotransfor-
mation products that can be detected in urine (Wang et al., 
2001). The determination of AFM1 in urine is correlated 
with the amount of AFB1 ingested, and as such is a good 
biomarker of exposure (Groopman et al., 1992). The aim 
of this study was to evaluate the occurrence of AFM1 in 
the urine of non-carriers and chronic carriers of HBV in 
the population of Maringa, southern Brazil.
MATERIAL AND METHODS
Study population
The study population consisted of 72 randomly se-
lected individuals divided into two groups: non-carriers 
and chronic HBV carriers. The group of non-carriers 
included 29 healthy adults with anti-HBs positive and 
HBsAg (surface antigen) negative results. All had been 
vaccinated against HBV. Age, race and schooling level 
similar to the group exposed. The group of chronic HBV 
carriers was composed of 43 patients adults diagnosed 
at two hospitals in the city of Maringa (Brazil) from 
March to June 2008, with HBsAg positive by more than 
six months. The voluntary participants each completed 
individual questionnaires. All participants signed a free 
and informed consent form. This study was approved by 
the Research Ethics Committee Involving Human Sub-
jects (COPEP), State University of Maringa (CAAE N. 
0007.0.093.000-08).
Data collection
The self-administered questionnaire for chronic 
HBV carriers covered personal data, alcohol and medica-
tion use, duration of HBV infection and laboratory data. 
Personal data including age and gender was collected 
from HBV non-carriers. Participants were provided with 
instructions regarding completion of the questionnaire and 
the collection of biological materials.
Blood samples were collected from HBV non-
carriers for detection of anti-HBs and HBsAg serologic 
markers. For both study groups, samples from first morn-
ing urine were collected in a 300 mL polyethylene bottle, 
identified and stored at -20 °C until analysis for AFM1.
Serological markers of HBV
Analysis of serologic markers for HBV antibody 
against surface antigen “S” (anti-HBs) and surface antigen 
S (HBsAg) was performed using the AxSym® and Che-
miluminescence System methods, respectively, according 
to the manufacturer’s instructions.
Urine AFM1 analyses
AFM1 and β-glucuronidase were purchased from 
Sigma Chemicals Co. (St. Louis, MO, USA). The solvents 
and chemical reagents used were analytical grade aceto-
nitrile (Mallinckrodt Baker, Xalostoc, Mexico), HPLC 
grade methanol (Mallinckrodt Baker, Phillipsburg, NJ, 
USA), potassium bromide (F. Maia Indústria e Comércio 
Ltda, Cotia, Brazil), acetone and anhydrous sodium sul-
fate (Vetec Ltda, Rio de Janeiro, Brazil), trimethylsilyl 
chloride (Merck, Hohenbrunn, Germany), acetic and 
nitric acid (Labsynth Ltda, Diadema, Brazil), toluene 
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(CAQ, Diadema, Brazil) and hydrochloric acid (Merck, 
Darmstadt, Germany). Nitrogen was purchased from AGA 
(Sundyberg, Switzerland) and Aflaprep®immunoaffinity 
columns were obtained from R-Biopharm Rhône Ltd. 
(Glasgow, Scotland).
AFM1 standard was diluted in acetonitrile to cre-
ate a stock solution of 7.61 µg/mL. Concentration of the 
prepared solution was performed according to the meth-
odology 971.22 described by the Association of Official 
Analytical Chemists (AOAC, 2005). Working solutions for 
the calibration curve, prepared by diluting in acetonitrile-
water (30:70 v/v), were 0.01, 0.03, 0.1, 0.2 and 0.3 ng/mL.
Urine samples were thawed at room temperature, 
homogenised by inversion and filtered through standard 
filter paper. Ten mL of 0.1 M sodium acetate buffer pH 
5.0 containing 0.4 mg/mL (500 U/mL) β-glucuronidase 
was added to 10 mL of filtered urine and incubated in a 
EV 015T water bath (Evlab, Londrina, Brazil) at 37 oC for 
17 hours (Kussak, Andersson, 1995).
After hydrolysis, AFM1 was extracted from urine 
samples on immunoaffinity columns. The column was 
conditioned with 10 mL of Milli-Q Plus ultrapure wa-
ter (Millipore, Bedford, MA, USA). Twenty mL of the 
sample was added, the column was washed with 10 mL 
water, dried by air flow, and AFM1 was eluted with 2 mL 
of acetonitrile in previously silanised tubes under a flow 
of less than 2 mL/min. The eluate was concentrated under 
nitrogen flow in a concentrator Tech Vap TE 0194 (Tecnal, 
Piracicaba, Brazil). The residue was frozen at -20 oC until 
chromatographic determination.
The eluate was resuspended in 400 µL acetonitrile-
water (30:70 v/v) and agitated in a KMC-1300V vortex 
(Vision, Korea). It was then filtered through a Sun-Sri 
(PTFE Titan 2 HPLC filter Yellow 17 mm, 0.45 µm) 
membrane. The standards and the filtered samples were 
analysed in an Alliance® HPLC system (Waters, Dublin, 
Ireland) attached to a quaternary pump and an automatic 
sample injection system at a volume of 100 µL. The fluo-
rescence detector used was a 2475 model (Waters, Dublin, 
Ireland) with an excitation wavelength of 365 nm and 
emission at 440 nm. A phenyl C-18 column 250 x 4.6 mm 
with 5 µm particles was used (XTerra, Dublin, Ireland). 
The isocratic system included an acetonitrile-water 
(30:70 v/v) mobile phase containing 1 mM potassium 
bromide and 1 mM nitric acid at a flow rate of 1.5 mL/min. 
Post-column derivation was performed with Kobra Cell® 
(R-Biopharm Rhône Ltd., Glasgow, Scotland) at 20A con-
nected to a 500 x 0.55 mm PTFE tube.
Quantification of AFM1 was performed using the 
calibration curve obtained from working solutions (0.01 
to 0.3 ng/mL or 0.8 to 24 pg/mL, depending on the dilu-
tion factor of the sample). Each solution was injected 
three times and the average of the replicates was used to 
construct the calibration curve. Linearity of the calibration 
curve was 0.9949. The detection limit was 0.13 pg/mL and 
the limit of quantification for the method was 0.40 pg/mL. 
The AFM1 retention time was 5.0 minutes. Precision and 
accuracy (recovery) were 5.9% and 91.7% in a concentra-
tion of 10 pg/mL (n=6).
Statistical analysis
For the statistical evaluation between the means of 
AFM1 detected in the urine of individuals in each group, 
the “t test” with a 95% confidence interval was performed 
using BioEstat 5.0 and Sigma Statistic 2.3.
RESULTS
The HBV non-carriers included 29 subjects with a 
mean age of 33 years (20 to 57 years) who presented anti-
HBs positive and HBsAg antigen negative results. There 
were 5 males and 24 females in this group. There were 43 
chronic HBV carriers with a mean age of 46 years (22 to 
60 years). Of these, 26 were males and 17 were females. 
Questionnaires that were answered appropriately provided 
the following data: 86.5% of patients were Caucasian, 
2.7% were Asian and 10.8% were African descent. The 
average time from diagnosis of HBV until the present 
study was six years. Laboratory tests previously carried 
out included: HBsAg (94.7%), anti-HBs (57.9%), anti-
HBe (52.6%), anti-HBc (47.4%), HBeAg (36.8%) and 
anti-HBc IgM (31.6%). Only 9.5% of patients reported 
having undergone viral load testing for hepatitis B.
Regarding the consumption of alcoholic beverages, 
73.7% of individuals reported that they do not drink and 
26.3% reported that they consume alcohol ‘frequently’. Of 
the 25% of patients that underwent treatment, lamivudine 
(14.3%) and interferon (3.6%) were the most common 
medications used. Other unspecified medications ac-
counted for 7.1% of the HBV carrier population.
Of 72 urine samples obtained from non-carriers and 
chronic HBV carriers, 21 (29.2%) presented quantifiable 
levels of AFM1 in urine, ranging from 0.67 to 7.87 pg/mL 
(Table I).
HBV non-carriers had detectable levels of AFM1 in 
5 (17.2%) of 29 analysed samples (Figure 1). All of the 
positive samples, 5/24 (20.8%), were from females. Two 
had concentrations between 0.6 and 3.0 pg/mL and 3 had 
concentrations ranging from 3.01 to 5.50 pg/mL. None of 
the samples had concentrations greater than or equal to 
5.51 pg/mL. Sixteen (37.2%) of 43 analysed samples were 
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positive for AFM1 in chronic HBV carriers. Nine (56.3%) 
were from female patients and 7 (43.8%) were from males, 
ranging between 0.6 to 8.0 pg/mL. The number of samples 
with concentrations ranging from 0.6 to 3.0, 3.01 to 5.50 
and 5.51 to 8.00 pg/mL were 5, 3 and 1 for females, and 
6, 0 and 1 for males, respectively.
DISCUSSION
The levels found of AFM1 in urine, 0.67 to 
7.87 pg/mL (29.2%), were lower than the value reported by 
Romero et al. (2010), who showed a prevalence of 65%, 
with levels ranging from 1.8 to 39.9 pg/mL in a Brazilian 
population. The difference between the data may have oc-
curred, since in our study only one sample was analyzed 
for each subject, and the seasonal variation and dietary 
data were not investigated.
These results showed a lower incidence and con-
centration of AFM1 in urine than other studies. Jolly et al. 
(2006) conducted a cross-sectional study in Ghana and 
detected AFM1 in the urine of 83 (91.2%) of the 91 partici-
pants studied, ranging between 10 and 11,562.36 pg/mg 
creatinine. In the Czech Republic, the occurrence of AFM1 
in urine was 57.6% of samples, ranging between 0.019 
and 19.219 pg/mg creatinine (Malir et al., 2006). Cheng 
et al. (1997) analysed 32 urine samples from patients in 
Taiwan and 138 from China, and AFM1 was found in 66% 
and 64% of the samples, respectively.
In China, Mykkanen et al. (2005) demonstrated 
the presence of AFM1 in the urine of 47.3% of young 
individuals (18-24 years) with an average level of 
40 pg/mL. Concentrations ranged between 10 and 
330 pg/mL. The presence of this biotransformation product 
in urine was not statistically different between subjects 
presenting HBsAg positive and HBsAg negative results. 
Our results were similar to this study in that there was no 
significant statistical difference between the average level of 
AFM1 in the urine of individuals from the non-carrier group 
FIGURE 1 - Distribution of AFM1 levels in the urine of 29 HBV non-carriers (control) and 43 chronic HBV carriers in Maringá, 
Brazil. (nd = not detected)
TABLE I - AFM1 in 72 urine samples from non-carriers and chronic HBV carriers from Maringa, Brazil
Population Gender N Positive Samples AFM1 in urine (pg/mL)
n (%) Range Average ± Standard Deviation
Non-carriers HBV Male 05 nd 0 -- --
Female 24 05 20.8 1.76-4.15a 2.81 ± 1.04
HBV carriers Male 26 07 26.9 0.74-6.77a 2.03 ± 2.13
Female 17 09 52.9 0.67-7.87a 3.24 ± 2.26
Total 72 21 29.1 0.67-7.87 2.74 ± 1.98
a = no significant statistical difference between the groups (p > 0.05); nd = not detected
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and from the chronic HBV carrier group (p=0.925). There 
was no significant statistical difference when levels of AFM1 
in the urine of females and males were compared (p=0.257).
In our study, the group of chronic HBV carriers 
showed AFM1 in 16 (37.2%) of 43 samples analysed. 
This result showed that this population was exposed to 
AFB1, and is therefore at risk of developing HCC, as sev-
eral studies have shown high morbidity from HCC due 
to exposure to aflatoxins and a high rate of chronic HBV 
infection (Qian et al., 1994; Sun et al., 1999; Wang et 
al., 2001). Sun et al. (1999) demonstrated that detectable 
urinary AFM1 levels above 3.6 ng/L were associated with 
increased 3.3-fold risk of HCC in male HBsAg carriers 
with chronic hepatitis. This fact is due to mutations in the 
third base of codon 249 of the p53 gene, since the studies 
showed a positive correlation between aflatoxin exposure 
and HCC with mutation 249ser (Sun et al., 1999; Bando et 
al., 2007). Anwar et al. (2008) concluded that have strate-
gies to reduce HCC with the use of markers of HBV, HCV 
(hepatitis C virus) and AFB1 exposure.
AFM1 is the major metabolite of AFB1 in quantita-
tive terms and excretion represents exposure within a 
period of 24 hours of sampling (Eaton, Gropman. 1994). 
Thus, the levels of AFM1 in urine were used as a biomarker 
for short-term exposure to AFB1 (Gan et al., 1988). This 
study showed AFM1 in the urine of 29.2% of the surveyed 
population, although differences were not statistically sig-
nificant between the non-carrier group and chronic HBV 
carriers regarding recent exposure to AFB1. However, 
there is evidence that the chronic HBV carriers have a 
higher risk of developing HCC due to additive interaction 
between AFB1 and HBV (Wu et al., 2009). Further studies 
using long-term exposure biomarkers, such as AFB1-N 7-
guanine and AF-albumin adducts, are required to assess 
the actual levels of long-term exposure to aflatoxins in the 
Brazilian population.
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